Noxilizer Board of Directors
Jack K. Ahrens, II is a founding General Partner of TGap Venture Capital Funds, headquartered in Kalamazoo, a Midwest focused venture capital fund that has raised over $46 million. Jack has been a venture capitalist since 1979; first as President of United Capital Corporation of Illinois (an SBIC), since 1983 as a General Partner of Pathfinder Venture Capital Funds I, II, and III. Prior to that he had seven years of experience in bank trust investments and operations. He has served on many Boards during his career including Afmedica, Inc., Central Data, Inc., Micro Business Applications, Inc., MedVantx, Inc., MinuteClinic, Inc., NeoChord, Inc., Rapid Diagnostek, Regenesis Biomedical and Vector General, Inc.
Alfred R. Berkeley III has been a Noxilizer individual investor since 2006. Mr. Berkeley has over 35 years of experience in the financial industry. He is currently the Chairman of the Board of Directors of Noxilizer. In addition, he is Vice Chairman of Gentag, Inc., a developer of technology for near field communications. Formerly, Berkeley Chaired the Board of Pipeline Financial Group, Inc, the parent of Pipeline Trading Systems, LLC, an equities and options trading company. Mr. Berkeley has served as President and then Vice-Chairman of The NASDAQ Stock Market, Inc. Before NASDAQ, he was a Managing Director of Alex Brown & Sons, a leading investment bank, and co-founded Alex Brown’s Technology Group in 1975. The Technology Group completed about 500 financial offerings for clients while he was associated with Alex Brown. Mr. Berkeley was a trustee of the Johns Hopkins University, served on the board of the Johns Hopkins University Applied Physics Laboratory, LLC. and is a Trustee of Allen University in Columbia, South Carolina. He is a Director of the World Economic Forum USA and was Chairman of XBRL US, a non-profit established to set standards for GAAP taxonomies to be used by public companies to report to the US Securities and Exchange Commission. He is a director of XBRL International. Mr. Berkeley is a graduate of the Wharton School of Finance of the University of Pennsylvania (MBA) and the University of Virginia (B.A.). He served as an officer in the United States Air Force.
John L. Brooks III is the President and CEO of the Joslin Diabetes Center. Joslin is the world’s leader in diabetes research, care, education and prevention. A well-known life sciences executive, Mr. Brooks has been a consultant to life science companies and was a co-founder of Prism Venture Partners, a venture capital firm which raised over $1.25 billion in capital. He was formerly a general manager at Pfizer/Valleylab in Boulder, Colo., where he developed and executed a minimally-invasive surgery and emerging businesses strategy. Prior to that, at Pfizer/Strato Medical, he led the growth of a rapidly evolving vascular access medical device business. Mr. Brooks has co-founded three life sciences companies including Insulet (PODD). He is a biotechnology advisory board member for Draper Labs and a member of M2D2, an early stage medical technology accelerator, and a board member of Suffolk University. He holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst. He is a Certified Public Accountant and a Certified Financial Planner.
Lawrence Bruder, Noxilizer’s current CEO, brings over 25 years of leadership and operational experience in large and small life science companies, including Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently, he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Much of his experience prior to Guava was at Becton Dickinson, where he held a number of significant positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high-level business development transactional activity; all of these being a critical part of Noxilizer’s needs. Mr. Bruder holds a B.S. from Rochester Institute of Technology and Master of Management in Marketing and Economics from the Kellogg School of Management at Northwestern University.
Herbert C. Buchanan Jr., President, IU Health Methodist and University Hospitals, is responsible for determining the strategic vision and priorities of two of the largest and busiest hospitals in Indiana.
Prior to joining IU Health in 2014, Buchanan served as chief executive officer for Howard University Hospital in Washington, DC. Before that, he served as chief operating officer for the University of Maryland Medical Center in Baltimore; as vice president of Operations at Northwestern Memorial Hospital in Chicago, IL; and as vice president of Operations & Process Improvement for the Huntsville Hospital System in Alabama.
A native of Washington, DC, Buchanan has an MBA from the Northwestern University JL Kellogg Graduate School of Management, as well as graduate and undergraduate degrees in mechanical engineering from the University of Michigan and the Massachusetts Institute of Technology (MIT), respectively.
Tomotaka (Tommy) Goji is Managing Partner at UTEC (The University of Tokyo Edge Capital), a Tokyo-based seed/early stage focused venture capital firm. Since he co-founded UTEC in 2004, he has raised three UTEC funds totaling approximately $300 million, which achieved nine IPO and seven M&A exits as of today. Prior to UTEC, he worked for Japan’s Ministry of Economy, Trade and Industry (METI), where he drafted "The Limited Partnership Act for Venture Capital Investment," an enactment for Japan’s private equity/venture capital funds. His portfolio companies where he served on board include: Tella (immunology, listed on Tokyo Stock Exchange JASDAQ), Morpho (digital image processing, listed on Tokyo Stock Exchange Mothers), and SAIAN Corporation (nitrogen dioxide sterilization, merged by Noxilizer in 2013).Tommy graduated from the University of Tokyo’s Faculty of Law and Stanford University’s Graduate School of Business.
Charles Immel is an independent healthcare industry advisor with broad global experience in medical devices and biopharmaceuticals. He has served most recently in executive leadership roles in Gambro, a large European manufacturer of renal therapy products recently acquired by Baxter Healthcare Corporation. Chuck was President of the Healthcare Division of STERIS Corporation, a leading global provider of medical devices in infection prevention and surgical environments. He started his career with Baxter Healthcare Corporation in the Biosciences Division where he held a variety of commercial leadership roles in North America, Europe and Japan. During his career he has launched numerous successful new products and services in the healthcare market by focusing on solutions that improve the efficacy and safety of care, while addressing overall system cost. He is a former member of BioOhio (Board of Trustees and Executive Committee), AdvaMed, American Chamber of Commerce Japan and Plasma Protein Therapeutics Association (Operations Committee). He is a graduate of The Ohio State University.
Dr. Edward Miller served as chief executive officer of Johns Hopkins Medicine and the 13th dean of The Johns Hopkins University School of Medicine. He retired from this position on June 30, 2012. As part of Dr. Miller's vision to improve access through the development of a regional, integrated health care delivery system, Howard County General Hospital was acquired and integrated into Johns Hopkins Medicine. Dr. Miller also led the effort to integrate Suburban Hospital and Health System in Bethesda, Maryland, Sibley Memorial Hospital in Washington, D.C., and All Children's Hospital in St. Petersburg, Florida, into Johns Hopkins Medicine. Under Dr. Miller's leadership, Johns Hopkins Medicine broadened its international presence to include relationships with hospitals and other health care-related institutions in the Americas, Europe, the Middle East and Asia, including an agreement to help Malaysia develop its first fully integrated private four-year graduate medical school and teaching hospital. One of his most significant accomplishments as Dean/CEO has been the massive rebuilding and renovation projects that have transformed the East Baltimore medical campus into a medical center where the most modern of buildings sit among the most historic including one of the largest hospital construction projects in the nation -- two new state-of-the-art hospitals for adult and pediatric patients. Other campus construction projects completed include: clinical and research buildings for the Sidney Kimmel Comprehensive Cancer Center, the Broadway Research Building, the Anne and Mike Armstrong Medical Educational Building, and the new Robert H. and Clarice Smith Building that is part of the Wilmer Eye Institute. An anesthesiologist who has authored or co-authored more than 150 scientific papers, abstracts and book chapters, Dr. Miller joined Johns Hopkins in 1994 as professor and director of the Department of Anesthesiology and Critical Care Medicine.
Jerry Parrott is President, Chief Executive Officer and a Director of BioMarker Strategies, a privately held cancer diagnostics company. Mr. Parrott previously served Human Genome Sciences as Vice President, Corporate Affairs and Public Policy from 2001 until the acquisition of HGS by GlaxoSmithKline in 2012. He formerly held senior public policy, corporate affairs, and other positions with Bristol-Myers Squibb Company, American Hospital Supply Corporation and Walgreen Company. As Principal of Policy Advocates Inc. from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital, Wyeth and others. During this period, he helped take public 3-Dimensional Pharmaceuticals, subsequently acquired by Johnson & Johnson, and InforMax, subsequently acquired by Invitrogen. He has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter. Since 2006, Mr. Parrott has served as Chairman and President of Maryland Health Care Product Development Corporation, a nonprofit venture capital fund committed to helping health care products companies grow and succeed in Maryland. He is a Director of MdBio, and the Tech Council of Maryland, and Senior Advisor to the Maryland Life Sciences Advisory Board. He formerly served as Chair of the Biotechnology Industry Organization (BIO) Committee on Outreach and Alliance Development, Chair of the Rx Partners health care reform coalition, Founding Director of BioHealth Innovation, Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the Committee for Economic Development.
Stephen Schaefer, J.D., is an intellectual property attorney and principal in the Minneapolis, MN office of Fish & Richardson, which he joined in 1995. He received his law degree from the University of Minnesota (1992) and also has degrees in electrical engineering and engineering management. Mr. Schaefer served as a judicial law clerk to Judge Alvin A. Schall of the Federal Circuit Court of Appeals in Washington, DC (1993-95), was an attorney at Pennie & Edmonds in New York City (1992-93), and served as an officer in the United States Air Force (1985-89). His expertise includes patent portfolio strategy and development; intellectual property agreements; and managing patent infringement litigation with the benefit of having worked as a full-time litigator early in his legal career. Mr. Schaefer was lead outside intellectual property counsel to Boston Scientific Corporation in connection with its $27B acquisition of Guidant Corporation, in 2005-06. He also advises several venture fund clients in connection with their investment decisions, and has conducted over 30 intellectual property due diligence studies over the years for those clients.